Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lissoni

Showing results (161-170 of 287) with videos related to

Pageof 29
Sort By:
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|January 1, 1986
Effects of tetrahydrocannabinol on melatonin secretion in manP Lissoni, M Resentini, R Mauri, et al.
The International Journal of Biological Markers|March 18, 1999
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic diseaseP Lissoni, F Rovelli, L Giani, et al.
Recenti Progressi in Medicina|April 20, 1999
[Therapy with melatonin does not suppress its endogenous production in healthy volunteers]P Lissoni, F Rovelli, S Pittalis, et al.
Journal of Biological Regulators and Homeostatic Agents|January 1, 1993
Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patientsP Lissoni, M Cazzaniga, A Ardizzoia, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1996
Is there a role for melatonin in the treatment of neoplastic cachexia?P Lissoni, F Paolorossi, G Tancini, et al.
The International Journal of Biological Markers|July 17, 2008
Correlation between soluble IL-2 receptor serum levels and regulatory T lymphocytes in patients with solid tumorsF Brivio, P Lissoni, L Fumagalli, et al.
Tumori|August 31, 1993
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapyP Lissoni, S Barni, G Tancini, et al.
In Vivo (Athens, Greece)|October 16, 2008
A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patientsP Lissoni, G Messina, D Parolini, et al.
Tumori|June 30, 1991
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical responseS Barni, P Lissoni, F Paolorossi, et al.
Tumori|August 31, 1994
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2P Lissoni, S Barni, M Andres, et al.
Pageof 29

Showing results (161-170 of 287) with videos related to

Sort By:
Pageof 29
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|January 1, 1986
Effects of tetrahydrocannabinol on melatonin secretion in manP Lissoni, M Resentini, R Mauri, et al.
The International Journal of Biological Markers|March 18, 1999
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic diseaseP Lissoni, F Rovelli, L Giani, et al.
Recenti Progressi in Medicina|April 20, 1999
[Therapy with melatonin does not suppress its endogenous production in healthy volunteers]P Lissoni, F Rovelli, S Pittalis, et al.
Journal of Biological Regulators and Homeostatic Agents|January 1, 1993
Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patientsP Lissoni, M Cazzaniga, A Ardizzoia, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1996
Is there a role for melatonin in the treatment of neoplastic cachexia?P Lissoni, F Paolorossi, G Tancini, et al.
The International Journal of Biological Markers|July 17, 2008
Correlation between soluble IL-2 receptor serum levels and regulatory T lymphocytes in patients with solid tumorsF Brivio, P Lissoni, L Fumagalli, et al.
Tumori|August 31, 1993
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapyP Lissoni, S Barni, G Tancini, et al.
In Vivo (Athens, Greece)|October 16, 2008
A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patientsP Lissoni, G Messina, D Parolini, et al.
Tumori|June 30, 1991
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical responseS Barni, P Lissoni, F Paolorossi, et al.
Tumori|August 31, 1994
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2P Lissoni, S Barni, M Andres, et al.
Pageof 29